Literature DB >> 19135574

Effect of sexual intercourse on the absorption of levonorgestrel after vaginal administration of 0.75 mg in Carraguard gel: a randomized, cross-over, pharmacokinetic study.

Vivian Brache1, Horacio Croxatto, Narender Kumar, Regine Sitruk-Ware, Leila Cochón, Veronica Schiappacasse, Irving Sivin, Carla Muñoz, Robin Maguire, Anibal Faundes.   

Abstract

BACKGROUND: The Population Council studied a pre-coital contraceptive microbicide vaginal product containing levonorgestrel (LNG) as active component and Carraguard gel as a vehicle (Carra/LNG gel) for couples who engage in occasional unplanned intercourse. The objective of this study was to evaluate the effect of sexual intercourse after vaginal application of Carra/LNG gel on serum levels of LNG in women and to assess LNG absorption by the male partner. STUDY
DESIGN: This was a randomized, cross-over, pharmacokinetic study including an abstinence arm and an arm in which couples engaged in sexual intercourse between 2 and 4 h after gel application. In each study arm, each woman received a single application of Carra/LNG gel (0.75 mg in 4 mL gel) followed by serial blood samples taken at 0, 1, 2, 4, 8, 24 and 48 h after gel application for LNG measurements. In the intercourse arm, LNG was measured in blood samples taken from the male partner before intercourse and at 4, 8 and 24 h after gel application in the female partner.
RESULTS: Time concentration curves for serum LNG levels showed a mean C(max) of 7.8+/-5.5 and 8.3+/-5.7 nmol/L, a mean T(max) of 6.2+/-5.9 and 7.5+/-5.7, and comparable area under the curve for the intercourse and abstinence arm, respectively. Pharmacokinetic parameters presented large variability between subjects, but excellent reproducibility within each subject. LNG was undetectable in 10 out of 12 male partners.
CONCLUSION: Sexual intercourse does not appear to interfere with vaginal absorption of LNG after application of a Carra/LNG gel. A vaginal pre-coital contraceptive gel is feasible.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19135574      PMCID: PMC2856066          DOI: 10.1016/j.contraception.2008.08.010

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  18 in total

1.  Comparison of microbicides for efficacy in protecting mice against vaginal challenge with herpes simplex virus type 2, cytotoxicity, antibacterial properties, and sperm immobilization.

Authors:  R A Maguire; N Bergman; D M Phillips
Journal:  Sex Transm Dis       Date:  2001-05       Impact factor: 2.830

2.  Intramuscular testosterone undecanoate with or without oral levonorgestrel: a randomized placebo-controlled feasibility study for male contraception.

Authors:  A Kamischke; D Plöger; S Venherm; S von Eckardstein; A von Eckardstein; E Nieschlag
Journal:  Clin Endocrinol (Oxf)       Date:  2000-07       Impact factor: 3.478

3.  Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial.

Authors:  Helena von Hertzen; Gilda Piaggio; Juhong Ding; Junling Chen; Si Song; György Bártfai; Ernest Ng; Kristina Gemzell-Danielsson; Amindavaa Oyunbileg; Shangchun Wu; Weiyu Cheng; Frank Lüdicke; Alenka Pretnar-Darovec; Rosemary Kirkman; Suneeta Mittal; Archil Khomassuridze; Dan Apter; Alexandre Peregoudov
Journal:  Lancet       Date:  2002-12-07       Impact factor: 79.321

4.  Pentosan polysulfate, a sulfated oligosaccharide, is a potent and selective anti-HIV agent in vitro.

Authors:  M Baba; M Nakajima; D Schols; R Pauwels; J Balzarini; E De Clercq
Journal:  Antiviral Res       Date:  1988-09       Impact factor: 5.970

5.  Experimental gonococcal genital tract infection and opacity protein expression in estradiol-treated mice.

Authors:  A E Jerse
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

6.  Combination of subcutaneous levonorgestrel implants and transdermal dihydrotestosterone gel for male hormonal contraception.

Authors:  P Pöllänen; V Nikkanen; I Huhtaniemi
Journal:  Int J Androl       Date:  2001-12

7.  Preliminary safety and acceptability of a carrageenan gel for possible use as a vaginal microbicide.

Authors:  C Coggins; K Blanchard; F Alvarez; V Brache; E Weisberg; P H Kilmarx; M Lacarra; R Massai; D Mishell; A Salvatierra; P Witwatwongwana; C Elias; C Ellertson
Journal:  Sex Transm Infect       Date:  2000-12       Impact factor: 3.519

8.  Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone.

Authors:  I T Gaw Gonzalo; R S Swerdloff; A L Nelson; B Clevenger; R Garcia; N Berman; C Wang
Journal:  J Clin Endocrinol Metab       Date:  2002-08       Impact factor: 5.958

9.  Effect of a single vaginal administration of levonorgestrel in Carraguard gel on the ovulatory process: a potential candidate for "dual protection" emergency contraception.

Authors:  Vivian Brache; Horacio Croxatto; Regine Sitruk-Ware; Robin Maguire; Juan Carlos Montero; Narender Kumar; Ana Maria Salvatierra; Ana Sofia Tejada; Leila Cochón; María Luisa Forcelledo; Pekka Lahteenmaki; Francisco Alvarez; Anibal Faundes
Journal:  Contraception       Date:  2007-06-13       Impact factor: 3.375

10.  Inhibition of Neisseria gonorrhoeae genital tract infection by leading-candidate topical microbicides in a mouse model.

Authors:  Steven E Spencer; Iris E Valentin-Bon; Kevin Whaley; Ann E Jerse
Journal:  J Infect Dis       Date:  2004-01-20       Impact factor: 5.226

View more
  2 in total

Review 1.  Priority strategies for India's family planning programme.

Authors:  Saroj Pachauri
Journal:  Indian J Med Res       Date:  2014-11       Impact factor: 2.375

Review 2.  New and emerging contraceptives: a state-of-the-art review.

Authors:  Luis Bahamondes; M Valeria Bahamondes
Journal:  Int J Womens Health       Date:  2014-02-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.